EA026617B1 - Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)уксусной кислоты - Google Patents
Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)уксусной кислоты Download PDFInfo
- Publication number
- EA026617B1 EA026617B1 EA201490998A EA201490998A EA026617B1 EA 026617 B1 EA026617 B1 EA 026617B1 EA 201490998 A EA201490998 A EA 201490998A EA 201490998 A EA201490998 A EA 201490998A EA 026617 B1 EA026617 B1 EA 026617B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- formula
- compound
- iii
- reaction
- alcohol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 88
- FATGTHLOZSXOBC-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid Chemical class C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1CC1=CC=C(C=CC=C2)C2=N1 FATGTHLOZSXOBC-UHFFFAOYSA-N 0.000 title claims description 24
- 230000008569 process Effects 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 82
- WPYJKGWLDJECQD-UHFFFAOYSA-N quinoline-2-carbaldehyde Chemical compound C1=CC=CC2=NC(C=O)=CC=C21 WPYJKGWLDJECQD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 93
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 61
- 238000006243 chemical reaction Methods 0.000 claims description 50
- 239000011541 reaction mixture Substances 0.000 claims description 33
- 239000012535 impurity Substances 0.000 claims description 31
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 30
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 26
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 23
- 230000002378 acidificating effect Effects 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000005406 washing Methods 0.000 claims description 11
- 239000003638 chemical reducing agent Substances 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000007858 starting material Substances 0.000 claims description 9
- JJIUISYYTFDATN-UHFFFAOYSA-N 5-fluoro-2-methyl-1h-indole Chemical compound FC1=CC=C2NC(C)=CC2=C1 JJIUISYYTFDATN-UHFFFAOYSA-N 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 239000000047 product Substances 0.000 description 47
- 239000000203 mixture Substances 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- -1 indole ester Chemical class 0.000 description 23
- 239000000543 intermediate Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 238000006722 reduction reaction Methods 0.000 description 13
- 230000009467 reduction Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 125000004494 ethyl ester group Chemical group 0.000 description 11
- 238000010992 reflux Methods 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XETODQFANWOPEC-UHFFFAOYSA-N 2-(5-fluoro-2-methylindol-1-yl)acetic acid Chemical compound FC1=CC=C2N(CC(O)=O)C(C)=CC2=C1 XETODQFANWOPEC-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229930194542 Keto Natural products 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- BHEFOTSBJZWUIS-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)ethyl]-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound CC=1N(CC(O)=O)C2=CC=C(F)C=C2C=1C(C)C1=CC=C(Cl)C=C1 BHEFOTSBJZWUIS-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- BUZYGTVTZYSBCU-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 description 1
- PCKBSRGNEIDFAK-UHFFFAOYSA-N 2-[(5-fluoro-2-methyl-1h-indol-3-yl)methyl]quinoline Chemical compound C1=CC=CC2=NC(CC=3C4=CC(F)=CC=C4NC=3C)=CC=C21 PCKBSRGNEIDFAK-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 150000004674 formic acids Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical compound CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201121557A GB201121557D0 (en) | 2011-12-15 | 2011-12-15 | Process |
| PCT/GB2012/000903 WO2013088108A1 (en) | 2011-12-15 | 2012-12-14 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201490998A1 EA201490998A1 (ru) | 2014-11-28 |
| EA026617B1 true EA026617B1 (ru) | 2017-04-28 |
Family
ID=45560499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490998A EA026617B1 (ru) | 2011-12-15 | 2012-12-14 | Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)уксусной кислоты |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9102658B2 (enExample) |
| EP (1) | EP2791129B1 (enExample) |
| JP (2) | JP6300277B2 (enExample) |
| KR (1) | KR102018929B1 (enExample) |
| CN (1) | CN104114548B (enExample) |
| AU (1) | AU2012351341B2 (enExample) |
| BR (1) | BR112014014604B1 (enExample) |
| CA (1) | CA2859281C (enExample) |
| CY (1) | CY1117087T1 (enExample) |
| DK (1) | DK2791129T3 (enExample) |
| EA (1) | EA026617B1 (enExample) |
| ES (1) | ES2557762T3 (enExample) |
| GB (1) | GB201121557D0 (enExample) |
| HR (1) | HRP20151422T1 (enExample) |
| HU (1) | HUE028257T2 (enExample) |
| IL (1) | IL233132A (enExample) |
| ME (1) | ME02348B (enExample) |
| MX (1) | MX342273B (enExample) |
| PL (1) | PL2791129T3 (enExample) |
| PT (1) | PT2791129E (enExample) |
| RS (1) | RS54523B1 (enExample) |
| SG (1) | SG11201402798RA (enExample) |
| SI (1) | SI2791129T1 (enExample) |
| SM (1) | SMT201500327B (enExample) |
| UA (1) | UA111868C2 (enExample) |
| WO (1) | WO2013088108A1 (enExample) |
| ZA (1) | ZA201404246B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| GB201322273D0 (en) * | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| GB201407807D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| EP3902795A1 (en) | 2018-12-27 | 2021-11-03 | Chiesi Farmaceutici S.p.A. | Pharmaceutical composition comprising spherical agglomerates of timapiprant |
| CN111978245A (zh) * | 2020-09-15 | 2020-11-24 | 上海毕得医药科技有限公司 | 一种3-氟-2-异丁基吡啶的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006092579A1 (en) * | 2005-03-01 | 2006-09-08 | Oxagen Limited | Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0415437A (pt) | 2003-10-14 | 2006-12-05 | Oxagen Ltd | composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| US7188489B2 (en) | 2005-04-12 | 2007-03-13 | Martello Russell A | Portable air conditioner |
| GB0605743D0 (en) * | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
| MX2009000801A (es) | 2006-07-22 | 2009-02-03 | Oxagen Ltd | Compuestos que tienen actividad antagonista crth2. |
| US20110124683A1 (en) | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| DK2250161T3 (da) | 2008-01-18 | 2014-01-27 | Atopix Therapeutics Ltd | Forbindelser med CRTH2-antagonistaktivitet |
| US8168673B2 (en) | 2008-01-22 | 2012-05-01 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| JP2011509990A (ja) | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| GB201121557D0 (en) * | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
-
2011
- 2011-12-15 GB GB201121557A patent/GB201121557D0/en not_active Ceased
-
2012
- 2012-12-14 CA CA2859281A patent/CA2859281C/en active Active
- 2012-12-14 EP EP12805725.4A patent/EP2791129B1/en active Active
- 2012-12-14 ME MEP-2015-218A patent/ME02348B/me unknown
- 2012-12-14 US US14/364,509 patent/US9102658B2/en not_active Expired - Fee Related
- 2012-12-14 MX MX2014007129A patent/MX342273B/es active IP Right Grant
- 2012-12-14 HU HUE12805725A patent/HUE028257T2/en unknown
- 2012-12-14 AU AU2012351341A patent/AU2012351341B2/en not_active Ceased
- 2012-12-14 JP JP2014546621A patent/JP6300277B2/ja not_active Expired - Fee Related
- 2012-12-14 SI SI201230408T patent/SI2791129T1/sl unknown
- 2012-12-14 EA EA201490998A patent/EA026617B1/ru unknown
- 2012-12-14 UA UAA201406835A patent/UA111868C2/uk unknown
- 2012-12-14 DK DK12805725.4T patent/DK2791129T3/en active
- 2012-12-14 PT PT128057254T patent/PT2791129E/pt unknown
- 2012-12-14 WO PCT/GB2012/000903 patent/WO2013088108A1/en not_active Ceased
- 2012-12-14 ES ES12805725.4T patent/ES2557762T3/es active Active
- 2012-12-14 PL PL12805725T patent/PL2791129T3/pl unknown
- 2012-12-14 CN CN201280066207.8A patent/CN104114548B/zh not_active Expired - Fee Related
- 2012-12-14 BR BR112014014604-7A patent/BR112014014604B1/pt not_active IP Right Cessation
- 2012-12-14 KR KR1020147017740A patent/KR102018929B1/ko not_active Expired - Fee Related
- 2012-12-14 HR HRP20151422TT patent/HRP20151422T1/hr unknown
- 2012-12-14 RS RS20150871A patent/RS54523B1/sr unknown
- 2012-12-14 SG SG11201402798RA patent/SG11201402798RA/en unknown
-
2014
- 2014-06-09 ZA ZA2014/04246A patent/ZA201404246B/en unknown
- 2014-06-15 IL IL233132A patent/IL233132A/en active IP Right Grant
-
2015
- 2015-12-23 CY CY20151101189T patent/CY1117087T1/el unknown
- 2015-12-23 SM SM201500327T patent/SMT201500327B/it unknown
-
2017
- 2017-07-28 JP JP2017146700A patent/JP2018008985A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006092579A1 (en) * | 2005-03-01 | 2006-09-08 | Oxagen Limited | Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid |
Non-Patent Citations (1)
| Title |
|---|
| APPLETON J E, ET AL: "A mild and selective C-3 reductive alkylation of indoles", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 34, no. 9, 26 February 1993 (1993-02-26), AMSTERDAM, NL, pages 1529 - 1532, XP002305011, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(00)60337-4 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5247728B2 (ja) | ベンズイミダゾール誘導体の製造方法 | |
| EA026617B1 (ru) | Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)уксусной кислоты | |
| KR20170029506A (ko) | 4-알콕시-3-히드록시피콜린산의 제조 방법 | |
| WO2012035553A1 (en) | Process for preparing androstenone derivatives | |
| KR20200050946A (ko) | 보호 l-카르노신 유도체, l-카르노신, 및 결정성 l-카르노신 아연착체의 제조 방법 | |
| AU2022326764B2 (en) | Synthesis of delta 9,11 steroids | |
| JP2000355587A (ja) | ３−ヒドロキシテトラヒドロフランの製造方法 | |
| RU2707043C1 (ru) | Способ получения гербицида имазамокса | |
| US6861525B2 (en) | Process for the preparation imidazo[1,2-A]pyridine-3-acetamides | |
| TW200804247A (en) | Process of producing O-methyl-N-nitroisourea | |
| US7265238B2 (en) | Process for preparing methyl 4-(aminomethyl)benzoate | |
| US20120259116A1 (en) | Novel Process for the Preparation of Paliperidone | |
| EP2834215B1 (en) | Process for making bendamustine | |
| WO2015177801A1 (en) | Novel process for the preparation of a lactam-containing compound | |
| HK1197671B (en) | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters | |
| NZ626732B2 (en) | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters | |
| JP2002371086A (ja) | ３−ブロモフェニルホスホン酸誘導体の製造方法 | |
| JP2018503640A (ja) | ４−シアノピペリジン塩酸塩を調製する方法 | |
| JP2001247549A (ja) | １位置換ヒダントイン類の製造方法 | |
| CZ20001012A3 (cs) | Imidazopyridinové deriváty a způsob jejich přípravy |